Tag Archives: apple

How Not To Wipe Out With Momentum

Summary Implementation costs and front-running make an index replication strategy inadvisable as a means to capture the momentum premium. The proven profitability and robustness of momentum must be balanced against the vulnerability to crashes and crowded trades. Combining value and momentum in order to exploit their typically negative correlation in stock holdings and alpha can improve a portfolio’s Sharpe ratio over that of either strategy alone. Momentum investors are like the surfers we watch from beaches along the Pacific coast. Both must catch a wave. Both attempt to ride it as it breaks. But the ability to glide away smoothly before being caught inside the inevitable crash(ing wave) that follows is what determines success. Momentum, one of a handful of equity factors that empirically displays robust equity returns, has recently become popular as investors explore factor investing. In the passive realm, investors are increasingly seeking to replicate cheap and transparent indices. But does index replication make sense in the case of momentum? We believe a momentum strategy implemented through an index-based approach has serious limitations. And although some active managers are quite adept at riding the momentum wave, it does require significant experience and skill. Our view is that momentum as an index replication strategy can be very dangerous, but incorporating it into an active value strategy is an opportune way to exploit its insights. Catching the Wave The investment industry borrowed the term “momentum” from the physical sciences. In physics, momentum is defined as mass (such as ocean water) in motion. When used in the sense of investing, momentum refers to movement in stock prices. Several explanations exist for the energy that creates the prolonged movement of stock prices higher or lower. The most convincing explanation, in our view, is that investors initially underreact to earnings surprises. Chordia and Shivakumar (2006) and Novy-Marx (2015) have shown that earnings momentum explains most of the momentum effect. Investors are, at first, slow to react to an unexpected uptick or downtick in earnings. But when the next earnings data are reported and they confirm the prior report, investors register the potential importance of the change in trend. If earnings are higher than expected, the momentum in price is upward. Subsequent confirming earnings releases may even cause euphoria and over-extrapolation of future earnings forecasts, reinforcing the fast-moving upward trajectory. The momentum investor benefits as the price reacts to subsequent earnings announcements and moves higher. Price momentum can also move in the opposite direction – down – with correspondingly negative outcomes for investors. We will discuss this “fly in the sunscreen” in the next section. Investors have good reason to want to catch the momentum wave. History shows that stocks with above-average performance in the prior year have tended to persist in producing short-term excess returns. This tendency is one of the strongest empirical regularities in finance, and has been documented across geographies and asset classes. Table 1 reports the average performance of momentum equity portfolios constructed for different definitions of momentum 1 and in different geographical markets: the United States, Europe, Japan, Asia-Pacific ex Japan, and Global. Momentum has consistently added value across markets, with the widely known exception of Japan – an outlier we would expect for any strategy with inherent randomness. (click to enlarge) The data also show that the risk-return characteristics of momentum are robust across time periods. Figure 1 plots the growth of one U.S. dollar invested in a momentum strategy in January 1927. By the end of the 87-year period in June 2015, it had grown quite steadily to a formidable $6,524, which compares to $4,078 for the market portfolio. (click to enlarge) Wiping Out Buying into positive price momentum – that is, purchasing a stock whose price subsequently and steadily rises – generates a capital gain for an investor. The catch is that, as in physics, what goes up must come down. The perfectly breaking 15-foot wave can quickly become dangerous and deadly. Predicting when that turning point will be, just as forecasting when the turning point in the price momentum of a particular stock or asset class will arrive, is no easy task. Missing that turning point can mean not only not locking in a gain, but more insidiously, being “caught inside the wave”, unable to sell before the downside of a momentum trend takes hold in the market. Accordingly, two predominant risks characterize a momentum strategy: substantial drawdowns, or crashes, and a crowded momentum trade, which makes the trading costs high enough to obliterate the alpha of the strategy for the careless momentum surfer. Let’s take a closer look at both of these. The crashes periodically experienced in a momentum strategy can be significant, as Figure 2 shows. The relentless upward climb of prices depicted in Figure 1 disguises (thanks to the log-scale of the chart) the sudden and abrupt drawdowns that a momentum investor must live with. These drawdowns usually occur following periods of heightened volatility, typically a function of a crisis event. Since 1927, drawdowns have generally been under 20%, but the granddaddy of all drawdowns was the 74% plunge in prices in the aftermath of the Great Depression. In the last 15 years, the U.S. equity market has been visited with two major negative momentum events: the first, a 31% drawdown after the tech bubble burst in 2000, and the second, a 57% drawdown in the wake of the 2008 global financial crisis. (click to enlarge) In a crash, the price momentum is typically concentrated in groups of stocks that the market particularly loathes and fears more than others, often distressed companies with high betas. These recent losers are sold as the negative momentum continues, until investors, satisfied with the new state of the world, view these stocks as cheap enough to be great investment opportunities. As the market shifts its perspective, the most-feared losers with high betas recover with a vengeance, and momentum investors are off to catch another wave. Crowded surf can create frustration as surfers compete for waves, leading to low wave counts and disappointing rides. The same experience looms for investors who chase the momentum trade. Momentum investors face the probability of a lower return as they “crowd in” to purchase a stock benefitting from positive momentum, which pushes the price up beyond fair value. When the momentum trend begins to reverse, momentum investors face the risk of not being able to sell at a reasonable price as large numbers “crowd out” to liquidate their positions. Essentially, the higher the price goes, the more investors are attracted to the trade, lowering its potential return except to the earliest adopters. Likewise, the lower the price goes, the faster investors seek to exit the trade, putting significant pressure on the price and the market’s ability to absorb the extent of the selling interest. The substantial risk from these interrelated forces – drawdowns and the crowded trade – act as a very practical and meaningful deterrent to more widespread adoption of a momentum investing strategy, even though it has been proven to be robustly profitable. Being cognizant of these risks, how can an investor best exploit the insights of a momentum strategy? Navigating Dangerous Currents A surfer knows to look for rip currents that can push her away from shore. In investing, particularly in passive strategies, dangerous currents lurk in the implementation process. One of these currents, the far-from-trivial price impact of rebalancing in popular indices, has been studied by a number of researchers: Shilfer (1986), Harris and Gurel (1986), Arnott and Vincent (1986), Goetzmann and Garry (1986), Jain (1987), Lamoureux and Wansley (1987), and Lynch and Mendenhall (1997), among others. Other researchers, including Novy-Marx and Velikov (2014) and Hsu et al. (forthcoming), have estimated the trading costs associated with index-like implementation of a momentum strategy. Hsu and his co-authors calculate the value added by a momentum strategy before and after transaction costs, as reported in Table 2 . The calculation shows that trading costs are higher than the potential benefits from the strategy. (A caveat: We do not believe this to be true in the case of an active manager with strong expertise in trading. 2 ) (click to enlarge) The practical implication of tracking an index, regardless of factor, is that when one investor places her rebalancing trades, all the other investors tracking the same index are also placing their rebalancing trades. Consequently, these investors are competing for the same stocks at the same time, generating upward pressure on price. When the factor is momentum, this phenomenon is aggravated by the fact that in order to squeeze the highest performance out of a momentum strategy, turnover of close to 100% a month is required. Thus, in the hands of inefficient implementers or automated indices, high turnover can mean high cost. Other currents that plague the implementation of passive strategies are the required transparency and broad disclosure of index rules. With today’s state-of-the-art technology, modern-day front-runners are able to reproduce index calculations and implement trades well before rebalancing announcements are made by the index calculator. Therefore, spreading trades over time cannot remedy the problem of prices pushed up significantly by front-running activity. As such, the front-runners will enjoy the factor premium – in this case, the momentum premium – and the index investors will provide this premium to them. Riding the Curl A pure momentum strategy, as we have just outlined, has both pros (demonstrated profitability and robustness) and cons (crashes and crowded trades). One strong “pro” we have yet to mention is the contribution that momentum can make to a value strategy. Adding momentum to a value strategy is similar to a surfer riding “peaky” waves that will give him a lengthy and exciting ride, leaving others to surf “close-out” waves with short, dull rides. In a value strategy, investors sometimes find themselves trading against momentum. As a stock becomes cheaper, a value strategy suggests buying more of it – the exact opposite of what a momentum strategy suggests. Not surprisingly, value and momentum strategies are usually negatively correlated, both in terms of stock holdings and alpha. Exploiting this negative correlation is essentially riding the curl – a value strategy conditioned on momentum. The combined strategy generally trades like a value strategy, but with purchases and sales delayed to benefit from momentum’s impact on prices. The addition of momentum need not boost turnover relative to a value investing strategy, and therefore, need not incur the high trading costs of a momentum strategy. Table 3 illustrates that combining value and momentum in a single strategy leads to significant improvements in portfolio risk-return characteristics. The improvements, largely attributable to consistent negative correlation that varies between -0.2 and -0.4, are robust. As shown in Table 3, the 50% value/50% momentum strategy’s Sharpe ratios are markedly higher than those for either strategy alone, indicating that a value strategy conditioned on momentum produces a significantly improved risk-return trade-off across regions, with the exception of Japan. (click to enlarge) Pipelining Momentum On paper, a momentum-based index against which active managers can benchmark makes sense – momentum is an important market driver that cannot be ignored. But in our opinion, passive implementation of a momentum strategy is not advisable. Front-runners and high transaction costs, a function of the strategy’s required high turnover, largely destroy the potential benefits of a momentum-based passive portfolio. Certainly, an active implementation of a momentum strategy, which incorporates a careful study of liquidity, makes sense for some investors. The more sophisticated investors who are aware of the strategy’s risks of crashes and crowded trades can benefit, but only when carefully implemented. Thus, the implementation capabilities of an active manager of a momentum strategy should be reviewed just as rigorously as, if not more so, the manager’s trading expertise. In our view, both passive and active standalone momentum-based strategies have the potential to wipe out the value-add that the momentum premium can bring to a portfolio. But incorporating momentum into a value strategy can open a performance pipeline for the investor who can make a clean escape as the wave closes behind him, crashing on the investors who are not exploiting momentum’s insights in a similar way. Endnotes: 1.) In Table 1, we report long-only strategies in the “Recent Winners” and “Recent Losers” columns. These portfolios comprise stocks with the highest and lowest past returns, respectively. The “t-Stat” column reports the t-stat of the long-short portfolio returns. The long-short portfolio holds recent winners and shorts recent losers. Three versions of the momentum strategy are reported for the United States, because three different holding periods were used to measure recent returns. 2.) For example, Frazzini, Israel, and Moskowitz (2012) analyze trading costs associated with an actual implementation of a momentum strategy by an active manager. Their main finding is that, with thoughtful implementation, transaction costs in a momentum strategy can be significantly reduced. References: Arnott, Robert, and Stephen Vincent. 1986. “S&P Additions and Deletions: A Market Anomaly.” Journal of Portfolio Management, Vol. 13, No. 1 (Fall):29-33. Basu, Sanjoy. 1977. “Investment Performance of Common Stocks in Relation to Their Price-Earnings Ratios: A Test of the Efficient Market Hypothesis.” Journal of Finance, Vol. 32, No. 3 (June):663-682. Chordia, Tarun, and Lakshmanan Shivakumar. 2006. “Earnings and Price Momentum.” Journal of Financial Economics, Vol. 80, No. 3 (June):627-656. Frazzini, Andrea, Ronen Israel, and Tobias Moskowitz. 2012. ” Trading Costs of Asset Pricing Anomalies. ” Fama-Miller Working Paper, Chicago Booth Research Paper No. 14-05 (December 5). Goetzmann, William, and Mark Garry. 1986. “Does Delisting from the S&P 500 Affect Stock Price?” Financial Analysts Journal, Vol. 42, No. 2 (March/April):64-69. Harris, Lawrence, and Eitan Gurel. 1986. “Price and Volume Effects Associated with Changes in the S&P 500 List: New Evidence for the Existence of Price Pressures.” Journal of Finance, Vol. 41, No. 4 (September):815-829. Hsu, Jason, Vitali Kalesnik, Helge Kostka, and Noah Beck. Forthcoming. “Navigating the Factor Zoo.” Research Affiliates Working Paper. Jain, Prem. 1987. “The Effect on Stock Price from Inclusion In or Exclusion from the S&P 500.” Financial Analysts Journal, Vol. 43, No. 1 (January/February):58-65. Lamoureux, Christopher, and James Wansley. 1987. “Market Effects of Changes in the Standard & Poor’s 500 Index.” Financial Review, Vol. 22, No. 1 (February):53-69. Lynch, Anthony, and Richard Mendenhall. 1997. “New Evidence on Stock Price Effects Associated with Changes in the S&P 500 Index.” Journal of Business, Vol. 70, No. 3:351-383. Novy-Marx, Robert. 2015. ” Fundamentally, Momentum Is Fundamental Momentum .” NBER Working Paper No. 20984 (February). Novy-Marx, Robert, and Mihail Velikov. 2014. ” A Taxonomy of Anomalies and Their Trading Costs .” NBER Working Paper No. 20721 (December). Shleifer, Andrei. 1986. “Do Demand Curves for Stocks Slope Down?” Journal of Finance, Vol. 41, No. 3 (July):579-590. This article was originally published on researchaffiliates.com by Chris Brightman , Vitali Kalesnik , and Engin Kose . Disclaimer: The statements, views and opinions expressed herein are those of the author and not necessarily those of Research Affiliates, LLC. Any such statements, views or opinions are subject to change without notice. Nothing contained herein is an offer or sale of securities or derivatives and is not investment advice. Any specific reference or link to securities or derivatives on this website are not those of the author.

XLV: Offering Investors An Interesting Blend Of Defensiveness, Price Appreciation And Income Growth

Recent weakness in the Healthcare sector led me to look at XLV as a means to increase my exposure to a space in the market that I’m attracted to. XLV offers me yield, income growth, and exposure to the entire healthcare sector, including many growth-oriented companies that I likely otherwise wouldn’t have exposure to. I’m typically not a fan of ETFs or other funds due to expense ratios; however, XLV’s is a very low 0.15%. On Monday, in the midst of the market wide sell-off, the destruction in the healthcare sector, specifically, caught my eye. I’ve been overweight in healthcare for awhile now, feeling strongly that as science and technology improves, modern medicine will so too. When looking for reliable growth in the markets, healthcare seems like the safest best. What’s more, many of the more established companies in the sector have been generous in the past with their shareholder returns and offer investors strong dividend growth histories. Recently, there has been drama in the space with regard to the pricing of drugs in the market place. This issue has made it into a political theater, and now, the sector as a whole is trading in response to announcements, and even tweets, made by politicians. Personally, I like my stocks to trade on earnings releases based on fundamental ratios; however, I understand there there is regulatory worry in the space, especially when presidential candidates are coming out strongly against what’s being referred to as “price gouging” in the media. I get it, the recent events centered around Turing Pharmaceuticals and its purchase of and ensuing price hike of the drug Daraprim has caused quite a stir. Honestly, I’m somewhat impressed by the notoriety that this has gotten on Capitol Hill – it seems as though this issue, more so than any other in recent memory, has drawn bilateral support from both Democrats and Republicans. And now, this sense of ire is being directed at the industry as a whole. However, I think it’s important for investors and politicians alike to understand that the Turing situation, compared to something that many view as being rather similar – we’ll use Gilead’s (NASDAQ: GILD ) pricing of Solvaldi, which made big news with regard to potential congressional oversight last year, as an example – is a very different situation. There are many more potential companies and/or drugs that I could use here, but regardless, most of these situations are like comparing apples to oranges. While Gilead spent the time, energy, and financial resources to develop Solvaldi and its other hep C treatments (treatments that don’t merely treat, but cure a potentially deadly disease that causes pain and suffering worldwide), all Turing did was buy the rights to an existing drug and hike the prices. Some might see both situations and think to themselves, “Either way, the treatments are overpriced and this is immoral.” I, however, see them as quite different beasts, with one being quite a bit more justified than the other. Biotech companies put a lot of resources towards their pipelines, and when they’re successful in developing treatments, they ought to be rewarded. As terrible as it might sound, when financial incentive to create such treatments disappear, I imagine that the treatments will as well. Governments worldwide have enough of a hard time funding themselves as it is… I don’t see them doing nearly as good of a job with biotech R&D as the private sector has. Everything comes with a cost in life, and the way I see it, good health is something that is actually worth paying for (and investing behind). But all personal opinions aside, the biotech space is no stranger to dramatic attention by the news media. For years, it seems, the healthcare sector, namely the more volatile biotech names within who are responsible for developing breakthrough drugs and treatments, have been either darlings or devils in the market’s eyes. This attention has allowed for bubbles to form, and pop, and form again. This volatility leads to more attention, and it seems as though the cycle is never ending. In recent years, when these bubbles have burst, the ensuing weakness turned out to be a great buying opportunity for those with the stomach to brave the bloodshed. Now, looking at present weakness, I have to decide if this will be the case again, or if the tides really changing due to a potential political overhaul of the system as a whole. And if I decide that this dip is just that, a dip, I need to figure out when and how should I add to my exposure in the space. Before I go on any further, I will note that I am not a doctor of any sort. I try my best to stay up-to-date on the pipelines of the companies that I own in the space, understanding what each company is setting out to do and whether or not it seems to be achieving its goals from both a scientific and financial standpoint. Due to my limited understanding of the science involved in the inner workings of biotech companies, this can be very difficult for me, and I admit that I rely on third-party sources a lot of the time for my information. I’ve found sources that I trust, and my system has worked out thus far; however, I think it’s worth mentioning that this strategy adds another element of speculation into the overall equation, because my due diligence is sometimes influenced by outside resources. And it’s this point – the fact that I think that many, if not most, self-directed investors don’t have a very good understanding of the healthcare sector as a whole (especially the biotech space, which drives a lot of growth) – that led me to write this article. Although I don’t currently own any ETFs in my personal portfolio, I’m tempted to buy shares of the Health Care Select Sector SPDR ETF (NYSEARCA: XLV ) on recent weakness. The overarching, diversified nature of this ETF would help to cover my tracks a bit as I wander through the sector, somewhat uninformed, while still allowing me to reap the rewards that the space has traditionally had to offer. There are several reasons why I’m attracted to the idea of buying XLV. Namely, right now I’m seeing a lot of deals in the space, and I don’t have enough money to enter into positions with all of them. And what’s more, even if I did have enough money to buy shares in all of them, it’s likely that the commissions I paid to half or even full positions for my portfolio, would equal out to be greater than the 0.15 total expense ratio that one pays when owning shares of this sector SPDR ETF. XLV’s holdings are comprised of many companies that I respect. Sure, there are some that I wouldn’t purchase outright in the market. This is typically the reason that I don’t own ETFs – I’d rather approve of all of the companies that I have exposure to, than simply buying buckets of stocks that contain shares of mismanaged or stingy companies; however, in this case, there are many more positives than there are negatives, and the overall sum of the parts with regard to XLV has received a passing grade. Another reason is this: Because of the diversified nature of the XLV portfolio, I’m given exposure to many more growth-oriented companies than I would be when stock picking, while still receiving a decent yield with above-average growth. I say above average because looking back at annual dividend payments investors received from holding the S&P 500 tracking index (NYSEARCA: SPY ) and XLV, during the last 11 years – from 2005 to 2015 – the income stream of those investors holding XLV had an 8.84% CAGR, while the income stream of those holding SPY had a 6.62% CAGR. The way I look at this, buying XLV allows me to have exposure to growth companies like Regeneron (NASDAQ: REGN ) or Celgene (NASDAQ: CELG ) – two companies with exciting pipelines, but no dividends – while still generating portfolio income. Here is a list of the fund’s top 10 holdings: (click to enlarge) (Source: XLV website ) Now, the downside to this higher growth potential, from both a stock price and dividend payment standpoint, is that my starting yield is lower when buying XLV than it would be if I were to narrow down my selection and purchase shares of healthcare dividend stalwarts like Johnson & Johnson (NYSE: JNJ ), Merck (NYSE: MRK ), Bristol-Myers (NYSE: BMY ), or even the aforementioned GILD, which isn’t exactly a “dividend stalwart”, though it is a company that I’m very long on, and one that I believe will pay a large part in my personal portfolio’s income stream moving forward. Right now, XLV is offering investors a 1.50% index yield, which is much lower than the 2%, 3% or even 4% yields that can be found from rather reliable companies in this space. Anyone investing in this index has to weigh these two options: single stock ownership with a potentially higher yield, or a more diversified, industry-wide exposure with less initial yield, but relatively similar dividend growth potential and greater price appreciation potential. Medical degree or not, it doesn’t take a genius to see that the healthcare sector has drastically outperformed the S&P 500 in recent years. Looking back even 20 years, we see that this sector of the market has been a top performer. This is clearly shown in this graph, which is a year or so outdated; however, I think it still has a point to prove, and I couldn’t find another with more recent data that painted such a clear, broad picture of the markets. (click to enlarge) (Source: Bernstein ) Looking at a similar data set through a more narrow lens, we see that over the last 10 years, XLV has outperformed not only the S&P 500, but also some of its major components that I choose because of my own interest in them (and the fact that I assumed other dividend income investors might be interested in them as well) – Johnson & Johnson and Pfizer (NYSE: PFE ) – by a long shot. (click to enlarge) Here is another image that I came across when looking at long-term asset class return results; I find it interesting that in this graph, not only has healthcare found itself among the very top performers since 2011, but in 2008, when the bottom fell out of the market, the healthcare sector was defensive in nature as well, with the second best overall sector-wide performance, behind only consumer staples. It’s not often that one is able to find defensiveness, growth potential, and income/income growth all in the same spot; however, it seems that with healthcare, investors get the complete trifecta. (click to enlarge) (Source: Sector SPDR Website ) And speaking of income, I went ahead and put these graphs together to show interested investors that not only do they get strong stock price appreciation potential with XLV, but also strong income growth. I know I mentioned the CAGR before, but this gives a more complete version of the picture. Here is a chart showing XLV’s quarterly dividends since 2005 (the fund’s inception date is 1998, but I thought a 10-year data set would suffice). (click to enlarge) Although the payments are a bit sporadic and not exactly predictable on a quarter by quarter basis, the overall trend is clearly to the upside. Here is another image I put together, comparing XLV’s dividend growth to that of SPY. As you can see, growth for XLV has been more reliable, especially in tough times. (click to enlarge) So, in conclusion, after looking over XLV as a potential holding, I came away impressed. Obviously, everyone’s portfolio management strategy is different, though I’m starting to realize that having exposure to these low-expense sector ETFs could be beneficial for me, especially from a diversification standpoint, and I will likely begin including them into my holdings. I am not currently long XLV, though it is a stock that is sitting near the top of my current buy list once the market calms down a bit and I get more clarity of certain global and Fed-related issues that I’d like to see play out before putting cash that I’ve recently raised back into the markets. I invite any and all readers to perform their own due diligence on XLV, because I think that right now, with it trading down 8% on the month, interested investors might find an attractive entry point into the space. I should also mention that I chose to focus on XLV rather than the often-talked-about iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) because of the lack of yield associated with the latter. I like the growth potential of sector, and especially the biotech space within; however, I’d like to get some yield from my money invested, so XLV seemed like the perfect compromise. Those looking for more of a growth pure play may want to take a closer look at IBB while you’re at your XLV due diligence as well.

Microsoft sets three important dates in October

Microsoft (MSFT) next month will open a flagship store in New York City just six blocks south of Apple’s (AAPL) flagship Manhattan store. Microsoft on Wednesday said it plans to open the store at 677 Fifth Ave. on Oct. 26. The five-floor, 22,269 square-foot location will be Microsoft’s first flagship store. It plans to open a second flagship store in Sydney, Australia, on Nov. 12. The flagship stores will feature the latest personal technology